SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Mipasetamab uzoptirine

Cat. No.: HY-P99734

CAS No.: 2304799-73-1

Target: TAM Receptor

Pathway: Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers[1].

In Vitro

Mipasetamab uzoptirine binds to both soluble and membranous AXL, and is rapidly internalized by AXL-expressing tumor cells, allowing release of PBD dimer, DNA interstrand cross-linking, and subsequent cell killing[1].
Mipasetamab uzoptirine selectively inhibits growth of AXL-positive human cancer cell lines (Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C)[1].
Mipasetamab uzoptirine (0 h, at 4°C) shows strong cell surface binding in SN12C cells, and colocalize well with lysosome at 1 h[1].
Mipasetamab uzoptirine increases DNA interstrand cross-links levels in SN12C cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C
Concentration:	0-20 nM approximately
Incubation Time:	5-8 days
Result:	Inhibited cell growth with IC50s of 0.47, 0.59, 0.02, 0.35, 0.11, 2.2, 0.83, 9.29, 14.62 nM respectively.

In Vivo

Mipasetamab uzoptirine (0.3-1 mg/kg, i.v.) inhibits tumor growth in MDA-MB-231 TNBC xenograft and SN12C xenograft mice model[1].
Mipasetamab uzoptirine (6 mg/kg, i.v.) is well tolerated and shows excellent stability in rats[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SN12C xenograft mice model[1].
Dosage:	0.3-1 mg/kg
Administration:	i.v.

Result:	Inhibited tumor growth and increased survival rate.

REFERENCES

[1]. Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA